Alnylam Pharmaceuticals, INC.: insider trades · United States · SEC (Form 4)

About Alnylam Pharmaceuticals, INC.

Alnylam Pharmaceuticals, Inc. is a U.S.-listed biopharmaceutical company traded on the Nasdaq (ticker: ALNY) in the United States. Founded in 2002 and commencing operations on June 14, 2002, the company is headquartered in Cambridge, Massachusetts (United States). Alnylam is widely recognized as a pioneer in RNA interference (RNAi) therapeutics, a gene-silencing approach designed to reduce the production of disease-causing proteins. Over time, the company has evolved from a pure R&D story into a commercial-stage rare-disease and specialty therapeutics platform with a growing international footprint. The company’s business is anchored by four marketed products: AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). These products address indications including transthyretin amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1. Alnylam’s first approved medicine, ONPATTRO, was the world’s first approved RNAi therapeutic, a landmark that established the company as the category leader and gave it an important first-mover advantage in a relatively young therapeutic class. Beyond the commercial portfolio, Alnylam maintains a pipeline spanning rare diseases, cardiovascular disease, and other genetic or biologically validated targets. From a competitive standpoint, Alnylam’s strengths lie in its scientific leadership, deep know-how in siRNA chemistry and delivery technologies, and a track record of translating RNAi biology into approved medicines. Its proprietary platform and human-genetics-driven discovery engine help it focus on targets where gene silencing can create meaningful clinical differentiation. At the same time, the company operates in a highly competitive and capital-intensive sector, where success depends on clinical validation, regulatory approvals, payer reimbursement, and durable commercial uptake. Its progress is also influenced by collaboration partners and the broader biotech funding environment. Geographically, Alnylam has its corporate headquarters in Cambridge, Massachusetts, and manages manufacturing and distribution through its global infrastructure, including a manufacturing site in Norton, Massachusetts. It sells medicines in the U.S. and internationally, with approved products and regulatory expansion efforts supporting broader geographic reach. Recent news has reinforced the company’s growth narrative. In early 2026, Alnylam launched its “Alnylam 2030” strategy and provided a strong revenue-growth framework for its commercial portfolio. In April 2026, the company highlighted further progress for AMVUTTRA in ATTR-CM and for zilebesiran, an investigational hypertension asset, while partner Regeneron announced an NDA submission for cemdisiran. For investors, Alnylam remains a differentiated Nasdaq biotechnology name in the United States, combining commercial momentum, pipeline optionality, and meaningful execution risk typical of innovative pharma companies.